For decades, scientists have understood that cancer becomes most dangerous when it travels — when rogue cells break free from a tumour and set up shop in distant organs. What they didn't fully understand was how those cells make the journey. Now, two French research teams have pulled back the curtain on that process, and their findings could reshape the future of cancer treatment.
The Great Escape
At INSERM's Tumor Biomechanics Lab in Strasbourg, a team led by researcher Jacky Goetz has spent over a decade studying how cancer cells spread through the body. Their latest discovery is striking: the walls of our blood vessels aren't passive bystanders in cancer's spread — they actively help tumour cells escape.
Here's how it works. When a cancer cell enters a blood vessel, it's too large for the space and blocks blood flow. The vessel wall responds by remodelling itself to push the cell out — inadvertently helping it colonise a new organ. The key player? Calcium ions. The more calcium signalling occurs, the more the vessel wall reshapes to expel the tumour cell.
"We remain humble about its direct application to patients," Goetz told French Healthcare, "but we open up possibilities by demonstrating that this crucial step can be controlled by existing drugs."
That last detail is worth pausing on. Calcium channel blockers — medications already widely prescribed for high blood pressure — could potentially be repurposed to interfere with this process. It's not a cure, but it's a remarkably promising lead built on medicine we already have.
A New Weapon Against the Toughest Cells
Meanwhile, at the Institut Curie in Paris, chemist Raphaël Rodriguez and his team have taken a different angle on the same problem. Their research, published in Nature, targets the cancer cells that standard treatments can't kill — the stubborn, drug-resistant cells with high metastatic potential.
Rodriguez's team developed a new class of small molecules called phospholipid degraders that exploit a natural process called ferroptosis — essentially using iron already present in aggressive cancer cells to trigger their self-destruction from the inside. In pre-clinical tests, the lead molecule, fentomycin (Fento-1), significantly reduced tumour growth in models of metastatic breast cancer and showed effectiveness against pancreatic cancer and sarcoma biopsies.
Clinical trials are still needed, but the approach is elegant: it turns cancer's own survival adaptations against it.
A Wave of Momentum
These French breakthroughs aren't happening in isolation. Experts are calling this period the "Therapeutic Revolution of 2026," and the momentum is real. In Spain, researchers have achieved pancreatic tumour regression using a triple-drug approach. Swedish scientists are advancing universal respiratory vaccines. And at Dana-Farber Cancer Institute in the United States, breakthroughs in personalised cancer vaccines and targeted therapies are moving swiftly through clinical trials.
It's worth remembering the stakes. Metastasis — the process these French teams are decoding — is responsible for the vast majority of cancer deaths worldwide. Any progress in understanding how it works represents a significant step toward saving lives.
Cautious Optimism
No one is claiming cancer has been solved. Both French teams are careful to note that their work is pre-clinical, and the road from laboratory to patient bedside is long and uncertain. But what makes this moment feel different is the convergence: multiple teams, across multiple countries, attacking the problem from different directions — and finding answers.
As Goetz put it, understanding the "great escape" of metastases opens entirely new therapeutic approaches. Not a single silver bullet, but a growing arsenal of possibilities.
For anyone whose life has been touched by cancer — and that's most of us — these discoveries offer something genuinely valuable: a reason to feel hopeful.
